Coldman Andrew J, Gondara Lovedeep, Smith Laurie W, van Niekerk Dirk, Ceballos Kathy, Krajden Mel, Cook Darrel, Quinlan David J, Lee Marette, Stuart Gavin Ce, Peacock Stuart, Martin Ruth Elwood, Gentile Laura, Franco Eduardo L, Ogilvie Gina S
Cancer Control Research, BC Cancer Research Centre, 675W 10th Ave, Vancouver, British Columbia, V5Z 1L3 Canada.
Cervical Cancer Screening Program, BC Cancer Agency, 650W 10th Ave, Vancouver, British Columbia, V5Z 4E6 Canada.
Br J Cancer. 2016 Dec 6;115(12):1487-1494. doi: 10.1038/bjc.2016.368. Epub 2016 Nov 17.
The HPV FOCAL Trial is a RCT comparing human papilloma virus (HPV) with Liquid Based Cytology (LBC) screening for cervical cancer. Results are presented for the comparison of the Safety and Control arms after two rounds.
HPV FOCAL included randomisation of women aged 25-65 into the Safety arm, where they were initially screened with HPV and the Control arm, where they received entry screening with LBC, with both arms screened again with LBC at 24 months.
There are 6203 (Safety) and 6075 (Control) women included in this analysis. For the Safety vs Control arms, Round 1 screening resulted in increased detection of cervical intraepithelial neoplasia 2 or worse (CIN2+),15.3 vs 10.4 per 1000, RR=1.48 (95%CI=1.08-2.03) and higher colposcopy referral rates, 5.6% vs 3.2%. LBC screening at 24 months resulted in similar colposcopy referral rates, 1.5% vs 1.9%, and decreased CIN2+ detection, 2.0 vs 4.7 per 1000, RR=0.43 (95%CI=0.21-0.88) in the Safety vs Control arms. CIN2+ detection and colposcopy referral rates declined with increasing age in both arms. One round of HPV screening detected similar levels of CIN2+ as two rounds of LBC screening.
CIN2+ detection at 2 years was lower in those screened by HPV, indicating an improved 2-year negative predictive value of the HPV test.
HPV FOCAL试验是一项随机对照试验,比较人乳头瘤病毒(HPV)与液基细胞学(LBC)筛查宫颈癌的效果。本文呈现两轮筛查后安全性组与对照组的比较结果。
HPV FOCAL试验将25至65岁女性随机分为安全性组(最初接受HPV筛查)和对照组(最初接受LBC筛查),两组均在24个月时再次接受LBC筛查。
本分析纳入6203名(安全性组)和6075名(对照组)女性。在安全性组与对照组中,第一轮筛查导致宫颈上皮内瘤变2级或更严重病变(CIN2+)的检出率增加,分别为每1000人中有15.3例和10.4例,RR = 1.48(95%CI = 1.08 - 2.03),且阴道镜转诊率更高,分别为5.6%和3.2%。24个月时的LBC筛查导致两组阴道镜转诊率相似,分别为1.5%和1.9%,而CIN2+检出率降低,安全性组与对照组分别为每1000人中有2.0例和4.7例,RR = 0.43(95%CI = 0.21 - 0.88)。两组中CIN2+检出率和阴道镜转诊率均随年龄增长而下降。一轮HPV筛查检测到的CIN2+水平与两轮LBC筛查相似。
HPV筛查者在2年时的CIN2+检出率较低,表明HPV检测的2年阴性预测值有所提高。